Highlights

  • Integrated Research offers an indicated fully franked dividend yield of approximately 7.0%, based on its most recent annual dividend of 2.0 cents per share.
  • The company suspended dividends for three consecutive years before reinstating a reduced payout in FY2024 and maintaining it in FY2025.
  • H1 FY2026 recorded a net loss of A$1.5 million and no interim dividend was declared, raising uncertainty around future payments.
  • A debt-free balance sheet and A$43.6 million cash position provide financial flexibility despite near-term earnings pressure.

On the surface, Integrated Research Limited (ASX:IRI) appears to offer a compelling income proposition. At a share price of A$0.285 as at 15 June 2026, the stock carries an indicated dividend yield of 7.02%, based on the most recent annual dividend of A$0.02 per share paid fully franked in October 2025. For Australian investors in the 30% or 45% tax bracket, the grossed-up yield stretches to approximately 10% — a number that stands out in any yield-seeking screen.

But yield alone is rarely the full story, and with IRI it is emphatically not. The company suspended its dividend for three consecutive financial years — FY2022, FY2023 and FY2024 — before reinstating a reduced payment of A$0.02 per share for FY2024 (paid September 2024) and FY2025 (paid October 2025). The first half of FY2026 produced a net loss of A$1.5 million, and the board again withheld an interim dividend. Management has explicitly flagged that profitability and cash generation are expected to decline over the next two to three years as product-led growth investment accelerates.

This article examines the sustainability of IRI's dividend against those realities — assessing payout ratios, free cash flow, the company's balance sheet strength, its ongoing revenue model transition, and the strategic risk that a micro-cap enterprise software business carries when it pledges to pay income while simultaneously funding a platform reinvention.

Company Overview

Integrated Research Limited was founded in 1988 and listed on the ASX in December 2000. Headquartered in Sydney, the company is a specialist developer of performance monitoring and observability software for business-critical IT infrastructure, with three core product verticals: payments network monitoring (Transact), unified communications and contact centre monitoring (Collaborate, covering Cisco, Microsoft Teams, Avaya and Genesys environments), and IT infrastructure performance management (Prognosis). The Prognosis platform underpins all three verticals.

IRI serves more than 400 enterprise clients across more than 60 countries, including some of the world's largest banks, telecoms companies and government agencies. Major client wins announced in FY2025 include a five-year, A$9.8 million renewal contract with JP Morgan Chase and a five-year contract with a top-10 US bank for the new High Value Payments (HVP) product. The company employs staff in Australia, the United States, the United Kingdom, Germany and Singapore, and generates the majority of its revenue in US dollars — introducing a structural currency exposure to AUD/USD movements.

With a market capitalisation of approximately A$51.5 million (as at 15 June 2026) and trailing twelve-month revenue of approximately A$68 million, IRI sits in micro-cap territory — a category that carries its own liquidity risk for individual investors and generally commands less analyst coverage. S&P Global data indicates no analyst currently carries a Buy recommendation; the most recent available rating is a Hold at a A$0.34 price target.

The company is in the midst of a multi-year strategic pivot — from a renewal-dependent licence fee model to product-led growth anchored in subscription-based, consumption-priced and cloud-hosted software. New products launched in recent periods include Iris (an AI-powered natural language observability interface), Prognosis Elevate (a cloud-hosted deployment option), and High Value Payments (a compliance and liquidity risk tool for banks processing large-value transactions). IR Labs, a dedicated AI and machine learning innovation unit based in the United States, is expected to release a standalone AI-powered product in beta during calendar year 2026.

Dividend Profile

Current Yield and Payment Terms

IRI's most recently declared dividend was A$0.02 per share for the financial year ended 30 June 2025, paid fully franked on 21 October 2025, with an ex-dividend date of 3 September 2025. At A$0.285, that equates to a 7.02% cash yield or approximately 10.0% grossed-up for investors who can use the attached franking credits. The dividend is paid annually (once per year). No interim dividend was declared for the half-year ended 31 December 2025.

History: A Long Track Record Interrupted by Multi-Year Suspension

IRI has paid dividends since at least 2009, originally on a semi-annual basis. Through the period from FY2015 to FY2020, the company paid combined annual dividends ranging from A$0.065 to A$0.075 per share, fully or substantially franked. As the company's financial performance deteriorated through FY2021 and FY2022 — revenue fell from A$78.5 million in FY2021 to A$62.9 million in FY2022 — the board omitted dividends entirely. No dividend was paid for FY2022, FY2023 or FY2024 as reported for those years, reflecting the company's net losses in FY2022 (small statutory profit but poor operating trajectory) and a major A$29.2 million statutory net loss in FY2023 (driven by large asset writedowns and impairments). Dividends were reinstated in September 2024 at the reduced level of A$0.02 per share, and that rate was maintained for FY2025.

The suspension was not formally announced as a permanent policy change but rather reflected practical constraints: the company had recorded operating losses, had been drawing down its cash buffer, and carried residual debt obligations. The reinstatement at a dramatically lower rate — A$0.02 versus peak payments of A$0.075 — signals the board's conservative approach post-crisis, but also underlines how far earnings power has declined from peak.

Franking and Grossed-Up Value

The FY2025 dividend of A$0.02 was declared fully franked at the 30% corporate tax rate. For a resident Australian investor on the top marginal rate of 45%, the gross dividend (including the franking credit of approximately A$0.0086 per share) equates to roughly A$0.0286 per share before personal tax is applied. Investors who are eligible to fully utilise the franking credit — superannuation funds, individuals in lower brackets, or those with adequate tax liability — can significantly enhance their effective after-tax return. Whether IRI will maintain full franking depends on it continuing to pay Australian corporate tax, which in turn requires sustained Australian-sourced taxable income.

Dividend Sustainability Analysis

Payout Ratio and Earnings Cover

Based on FY2025 diluted EPS of approximately A$0.074 (NPAT of A$13.36 million divided by 180 million diluted shares), the declared dividend of A$0.02 per share implies a payout ratio of approximately 27%. That is conservative in absolute terms and on a statutory earnings basis appears well-covered. Stock Analysis data shows the payout ratio at 48.87% on a TTM basis, reflecting the trailing net income position as of December 2025, when the half-year loss has reduced the rolling earnings base.

The cited screen context refers to diluted EPS TTM of A$0.04, implying TTM net income of roughly A$7.2 million. On that basis, a A$0.02 dividend equates to a payout ratio of approximately 50% — still covered by earnings, but with very little headroom before any further earnings deterioration would push the payout ratio above 100%.

Critically, management has explicitly stated that profitability will be lower over the next two to three years as product-led growth investment ramps. If NPAT falls materially from FY2025 levels — which seems likely given the H1 FY26 net loss — earnings cover will become uncomfortably thin or disappear entirely.

Free Cash Flow Coverage

IRI's free cash flow record is more reassuring than its statutory earnings history, largely because the company does not capitalise research and development expenditure. Unlike many software peers, IRI expenses all software development costs as incurred, meaning there is no inflated intangible asset line on the balance sheet from deferred R&D, and no risk of future write-downs that reverse apparent profitability. The goodwill impairments and asset writedowns that drove the A$29.2 million net loss in FY2023 were associated with earlier accounting decisions now largely resolved.

Operating cash flow has held up better than earnings through the transition period: A$21.1 million in FY2021, A$16.9 million in FY2022, A$13.8 million in FY2023, A$13.0 million in FY2024 and A$8.7 million in FY2025. Free cash flow (after minimal capital expenditure, which typically runs at A$0.3 million to A$0.5 million per annum given the asset-light nature of the business) has also declined but remained positive: A$20.8 million, A$16.6 million, A$13.5 million, A$13.0 million and A$8.2 million respectively over the same periods.

The total FY2025 dividend payout was approximately A$3.5 million (roughly 177 million shares at A$0.02 each). Against FY2025 operating cash flow of A$8.7 million, the dividend consumed 40% of operating cash flow — a meaningful but manageable proportion. However, if H1 FY26 is indicative of the full year, operating cash flow on an annualised basis may deteriorate significantly, and that 40% ratio would rise sharply.

Balance Sheet: Net Cash Position

A significant mitigant is IRI's net cash position. Cash at bank rose to A$43.6 million at 31 December 2025, up 8% from A$40.6 million at 30 June 2025, and the company carries no material debt. Enterprise value, as estimated by Stockopedia, is approximately A$8.2 million — implying the net cash balance alone represents a substantial fraction of market capitalisation. This cash buffer gives the board the practical ability to sustain dividend payments even in a period of operating losses, but doing so would represent a partial capital return rather than an income stream backed by earnings.

Management has indicated the strong cash position will be deployed to fund accelerated product-led growth investment in FY26 and beyond. If a meaningful portion of that A$43.6 million is earmarked for R&D spending (expensed, not capitalised), operating cash flow will be directly reduced — making the cash buffer and the dividend simultaneously less available.

Revenue Stability and Subscription Transition

IRI's statutory revenue has been highly volatile because it is driven primarily by the annual renewals book — the aggregate value of multi-year licence contracts up for renewal in any given year. This fluctuates materially from period to period. Statutory revenue fell from A$83.3 million in FY2024 to A$68.3 million in FY2025 — an 18% decline — as the FY2025 renewals book was softer. Pro forma revenue, which restates term licence fees on a straight-line basis to approximate a subscription accounting view, was far more stable: A$74.8 million in FY2024 versus A$74.3 million in FY2025, a decline of less than 1%.

The gap between statutory and pro forma revenue is a known structural feature of IRI's model. It is neither misleading nor unusual for a software company still selling multi-year term licences on an upfront basis. However, it does mean statutory earnings and operating cash flow will continue to swing based on the annual renewals composition — adding inherent unpredictability to dividend coverage assessments.

Encouragingly, consumption-based (subscription) revenue grew 77% year-on-year to A$3.9 million in FY2025, new client licence revenue grew 31% to A$6.7 million, and in H1 FY26 new client licence revenue rose 12% and expansion licence revenue rose 110% on the prior corresponding period — albeit from a low base. These metrics suggest early traction with the product-led strategy. However, subscription and new business revenue collectively represent a small portion of IRI's total revenue base, insufficient at present to offset renewals volatility or churn.

R&D Capitalisation Quality

IRI's approach to R&D expenditure is notably conservative relative to many ASX-listed software companies. Management has confirmed that all software development costs are expensed as incurred rather than capitalised to the balance sheet. This means the company's reported R&D expense line is a real cash cost, reducing reported earnings and operating cash flow in the year incurred. There is no build-up of intangible assets from deferred development costs that could mask true cash consumption or require future write-down. R&D as reported ran at approximately A$13.5 million in FY2025 and A$12.8 million in FY2024, though it was significantly higher (around A$22–A$24 million) in FY2022 and FY2023 before the strategic restructure.

This conservative accounting approach improves the quality of IRI's reported earnings and cash flow — what you see is closer to economic reality than at companies that aggressively capitalise development spend. The trade-off is that the income statement absorbs the full burden of investment year by year, contributing to earnings volatility.

Management Commentary on Dividends

The FY2025 results announcement noted a 'final dividend declared of 2.00 cents per share, fully franked,' without providing explicit forward guidance on dividend policy. Management's observation that 'investment in product-led growth is expected to reduce profits over the short to medium term' is the closest the company came to flagging dividend risk. The H1 FY26 results announcement (26 February 2026) did not declare an interim dividend and did not comment directly on the FY2026 final dividend outlook. The absence of interim dividend and the net loss position make a FY2026 final dividend a live question rather than a certainty.

Does the Yield Reflect Concern?

A 7% yield on a fully franked small-cap software stock almost always reflects elevated risk perception rather than generous income. IRI's share price has fallen dramatically from its peak of approximately A$3.85 in 2020, compressing market capitalisation and mechanically inflating the yield on a static dividend. The stock has underperformed both the broader ASX and the technology sector substantially over a one and three-year horizon. The elevated yield is not a sign of corporate generosity — it is a signal that the market has materially de-rated the company and is pricing in ongoing uncertainty around both earnings and dividend continuity.

Sector-Specific Risks

Revenue Model Transition Risk

Transitioning a software business from upfront licence fees to subscription or consumption-based pricing is inherently disruptive to near-term financials. During the transition window, the company simultaneously loses high-value upfront licence recognition and must build recurring revenue incrementally. IRI's management has been transparent about this tension, noting that statutory revenue performance 'trends with the renewals book' and that new client and expansion revenue is 'not yet sufficient to offset fluctuations in the annual renewals book and persistent churn.' Until subscription revenue becomes large enough to provide genuine base-level stability, earnings will remain highly sensitive to the composition of any given year's renewal book.

Customer Concentration and Churn

IRI's blue-chip client base includes some of the world's largest financial institutions and telecoms operators. While this concentration speaks to product quality, it also means the loss or non-renewal of a single major client can have a disproportionate impact on revenue. The H1 FY26 results referenced an 'expected credit loss largely associated with one client' — a single counterparty event that contributed to the EBITDA swinging from a profit of A$4.6 million to a loss of A$3.1 million. IRI also acknowledged 'persistent churn' as an ongoing structural challenge.

Competitive Dynamics

The performance monitoring and observability software market is intensely competitive. IRI competes with large, well-capitalised vendors — including NICE Systems, Cisco, Genesys, and a growing cohort of cloud-native monitoring platforms and AI-first observability startups — for enterprise contracts. IRI's differentiation lies in its deep integration with legacy unified communications infrastructure, its payments monitoring capability, and the longevity of its Prognosis platform. However, as enterprise UC infrastructure migrates to cloud-native architectures, the risk exists that IRI's on-premises-oriented strength becomes a competitive liability over the medium term unless Prognosis Elevate and Iris successfully bridge the gap.

Cash Conversion and Investment Horizon

Management has guided that the product-led growth investment horizon will span at least two to three years before meaningful revenue contribution materialises. This represents a prolonged period during which operating cash flow may remain compressed, demanding careful capital allocation between product investment, balance sheet maintenance and any dividend commitment. The company's expensing of all development costs (rather than capitalisation) means the full cash burden of investment flows immediately through operating cash flow — leaving less room for dividend payments.

Red Flags

  • Dividend suspension history: IRI omitted dividends entirely for FY2022, FY2023 and the year through to the FY2024 payment — a three-year gap that demonstrates willingness to cut income when earnings deteriorate.
  • H1 FY26 net loss: The half-year to December 2025 produced a net loss attributable to members of A$1.5 million, and no interim dividend was declared — the first half of FY2026 is already a negative earnings period.
  • Management guidance on falling profits: The company has openly stated that profitability and cash generation are expected to decline over the next two to three years, directly challenging dividend sustainability.
  • Softer FY2026 renewals book: Management flagged at the FY2025 results that FY2026 renewals are softer than FY2025. This implies statutory revenue pressure in FY2026, further compressing earnings and cash flow.
  • Revenue decline: Statutory revenue fell 18% from A$83.3 million to A$68.3 million in FY2025. TTM revenue (to December 2025) was approximately A$67.8 million, with the trend still declining.
  • Single-client credit loss: A material expected credit loss from one client in H1 FY26 illustrates the concentration risk embedded in IRI's client portfolio.
  • Small market capitalisation: At A$51.5 million, IRI is a micro-cap stock with limited analyst coverage, reduced institutional support, and potentially wider bid-offer spreads that affect liquidity for investors.
  • Weak EPS trend: Diluted EPS has fallen from A$0.05 in FY2021 to A$0.07 in FY2024 and A$0.074 in FY2025 — and TTM EPS of A$0.04 already implies deterioration into the current financial year.

Bull Case

  • Net cash fortress: A$43.6 million in cash with no debt means IRI has the practical capacity to fund dividends even through a period of operating losses, and provides a runway to execute product strategy without needing external capital.
  • Fully franked at a meaningful yield: For superannuation funds and low-tax investors, the grossed-up yield above 10% (based on the FY2025 payment) is material income even if nominal.
  • No R&D capitalisation: The quality of IRI's cash flow reporting is high. Because all development costs are expensed, free cash flow is not inflated by deferred capitalisation — operating cash flow of A$8.7 million in FY2025 versus a A$3.5 million dividend payout is a genuine 2.5x coverage ratio.
  • Sticky blue-chip client base: Long-tenure relationships with top-10 global banks and major telecoms operators provide a degree of revenue floor that pure-play startup-oriented competitors cannot replicate.
  • Early growth metrics improving: New client revenue up 12% and expansion revenue up 110% in H1 FY26 on small but growing base. A successful product pivot could inflect earnings meaningfully.
  • AI and cloud products under development: Iris (launched in H1 FY26), Prognosis Elevate and the IR Labs standalone product address growing demand for AI-assisted observability in complex enterprise environments.

Bear Case

  • Dividend may not survive FY2026: With H1 FY26 producing a net loss, FY2026 full-year earnings could be negative or minimal. The board may elect not to declare a FY2026 final dividend — reverting to the suspension precedent set in FY2022 to FY2024.
  • Ongoing revenue decline: Statutory revenue has fallen 18% in FY2025 and early FY2026 data shows a further 2% decline. A prolonged revenue erosion would progressively erode the cash buffer used to support dividends.
  • Product strategy remains unproven: Iris, Elevate and HVP are early-stage commercial products. There is no track record of meaningful revenue from these offerings, and the medium-term revenue inflection management targets is speculative at present.
  • Competitive displacement risk: Cloud-native observability platforms and AI-first entrants may displace IRI's on-premises Prognosis deployments as enterprise infrastructure migrates to cloud over the medium term.
  • Currency exposure: With the majority of revenue denominated in US dollars and costs in AUD, the company is exposed to adverse AUD/USD movements. In FY2025, currency added A$1 million in pro forma revenue — a tailwind that may not persist.
  • Market de-rating risk: At A$0.285, the stock is already 92% below its 2020 peak. If the dividend is cut again and the growth strategy takes longer than anticipated, further re-rating downward is plausible.

Latest News and Recent Developments

IRI's most recent major announcement was its H1 FY26 interim results on 26 February 2026, reporting revenue of A$28.3 million (down 2% on the prior corresponding period), an EBITDA loss of A$3.1 million (compared to an EBITDA profit of A$4.6 million in H1 FY25), and a net loss attributable to members of A$1.5 million. The cash balance improved to A$43.6 million. No interim dividend was declared.

Key product milestones achieved in H1 FY26 included the commercial launch of Iris — IRI's natural language AI interface for multi-vendor observability — and the release of Prognosis Elevate, the cloud-hosted deployment option for Prognosis. The High Value Payments product completed its first client implementation with a top-10 US bank. IR Labs remains on track for a beta release of a standalone AI product in calendar year 2026.

New business metrics showed modest but positive early traction: new client licence revenues grew 12% to A$4.6 million and expansion licence revenues grew 110% to A$1.6 million compared to H1 FY25. The Americas market declined 6% in the half — partially attributable to timing delays and market uncertainty that management expects to partially recover in H2 FY26.

At the AGM in November 2025, CEO Ian Lowe reinforced the product-led growth narrative, emphasising that the company's foundational investment phase was underway and that meaningful revenue contribution from new products was a medium-term objective rather than an immediate financial year outcome.

As at 15 June 2026, no further ASX announcements regarding FY2026 full-year results, dividends or guidance updates appear to have been made public beyond the February interim results. The full-year FY2026 results would ordinarily be expected in August 2026.

Dividend Sustainability Rating

Rating: High Risk

IRI's dividend is rated High Risk. The reasoning is as follows. While the FY2025 statutory payout ratio was moderate at approximately 27%, and free cash flow covered the distribution roughly 2.5 times, the forward trajectory is materially adverse. The H1 FY26 net loss, the absence of an interim dividend, management's own guidance of declining profitability over two to three years, a softer FY2026 renewals book, and the company's established precedent of omitting dividends during earnings downturns collectively make the continuation of the FY2026 final dividend uncertain. The dividend is not backed by a formal payout policy, is not protected by a dividend reinvestment plan, and is explicitly discretionary. The A$43.6 million net cash buffer provides the practical capacity to pay a A$3.5 million dividend even from a loss-making position — and that is the primary argument for the rating not being 'Unsustainable.' However, paying dividends from a cash reserve during a deliberate phase of accelerated investment spending would dilute the very capital the company needs to execute its growth strategy. Investors should treat the FY2026 dividend as a possible but not probable outcome pending August 2026 full-year results.

Investor Takeaway

Integrated Research Limited presents a genuinely complex picture for investors considering it as an income holding. The 7% fully franked yield is one of the more attractive headline numbers available in the ASX micro-cap technology sector, and the company's net cash balance of A$43.6 million with no debt is a meaningful structural positive. However, the dividend has been suspended before — for three consecutive years — and the current operating environment is deteriorating rather than improving. Management has been transparent that the product-led growth investment phase will weigh on earnings and cash flow for an extended period.

Income-focused investors who are attracted by the yield should note that it is elevated primarily because the share price has fallen so far — not because the dividend quantum has grown. A dividend funded by balance sheet cash rather than operating earnings is a categorically different proposition from an income perspective. Investors considering IRI should evaluate whether the company's AI and product transformation strategy is credible and executable over a two to three year horizon, and size any position accordingly — understanding that the dividend itself may be the secondary consideration in an investment thesis that ultimately turns on whether Iris, Elevate and High Value Payments can restore sustainable revenue growth.